Home / Products / Cancer / Hodgkin Lymphoma

Hodgkin Lymphoma


Available treatments for Hodgkin Lymphoma
You can order a treatment for Hodgkin Lymphoma via TheSocialMedwork if it has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.
Read more about Hodgkin Lymphoma below.
drip
View Product

Keytruda

(pembrolizumab)

by: Merck & co
for: Head and Neck Cancer / Lung Cancer / Urothelial Carcinoma / Skin Cancer / Lymphoma / MSI-H or dMMR solid tumours / Gastric Cancer
from: 1626.51
• EMA approved (EU)
• FDA approved (USA)
• TGA approved (AUS)

drip
View Product

Opdivo

(nivolumab)

by: Bristol-Myers Squibb
for: Colorectal Cancer / Head and Neck Cancer / Hodgkin Lymphoma / Kidney Cancer / Lung Cancer / Skin Cancer / Bladder Cancer / Liver Cancer
from: 585.38
• EMA approved (EU)
• FDA approved (USA)
• PMDA approved (JAP)
• TGA approved (AUS)

unknown
Enquire now

We may still be able to get it for you, provided that:

• it hasn't been approved and/or isn't available in your country
• you and your treating doctor have evaluated that the medicine is suitable for you, and your doctor writes a prescription for it.


About hodgkin lymphoma

Lymphoma is the most common blood cancer; it’s two main forms are Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Lymphoma occurs when cells of the immune system called lymphocytes, a type of white blood cell, grow and multiply uncontrollably. HL is characterized by the presence of very large cells called Reed-Sternberg (RS) cells, although other abnormal cell types may be present. HL usually starts in the lymph nodes and often spreads from one lymph node to another and can spread to other organs. HL has been divided into two main classifications: classical HL (CHL), which accounts for 90 to 95 % of cases, and nodular lymphocyte predominant HL. The type of HL a patient has may affect their treatment choices [1].

HL, also known as Hodgkin disease, is less common than NHL. Although HL can occur in both children and adults, it is most commonly diagnosed in young adults between the ages of 20 and 34 years [1]. The global incidence of HL in 2012 was 66,000 [2]. Over 80 % of patients with HL survive for five years, and many are cured. Most patients treated for HL will receive some form of chemotherapy, and sometimes radiation therapy, as their first treatment [1].

The above products may be suitable for treating patients with HL. We recommend that you discuss the suitability of possible treatment options with your doctor. For further information please contact our support team at support@thesocialmedwork.com.


Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.



Our service uses cookies.